Phospholamban: a crucial regulator of cardiac contractility

Nat Rev Mol Cell Biol. 2003 Jul;4(7):566-77. doi: 10.1038/nrm1151.


Heart failure is a major cause of death and disability. Impairments in blood circulation that accompany heart failure can be traced, in part, to alterations in the activity of the sarcoplasmic reticulum Ca2+ pump that are induced by its interactions with phospholamban, a reversible inhibitor. If phospholamban becomes superinhibitory or chronically inhibitory, contractility is diminished, inducing dilated cardiomyopathy in mice and humans. In mice, phospholamban seems to encumber an otherwise healthy heart, but humans with a phospholamban-null genotype develop early-onset dilated cardiomyopathy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Calcium-Binding Proteins / physiology*
  • Calcium-Transporting ATPases / metabolism*
  • Cardiomyopathy, Dilated / physiopathology*
  • Humans
  • Mice
  • Mice, Knockout
  • Myocardial Contraction / physiology*
  • Sarcoplasmic Reticulum / enzymology
  • Sarcoplasmic Reticulum / physiology*
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases


  • Calcium-Binding Proteins
  • phospholamban
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases
  • Calcium-Transporting ATPases